EGFR and non-small cell lung carcinoma: Activating mutation of epidermal growth factor receptor (EGFR) is the primary oncogenic driver of NSCLC, with up to 50% of NSCLC patients harboring mutations in the EGFR tyrosine kinase domain (3, 4, 5).